Golidocitinib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07300514CT.gov Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma | — | Recruiting | — | — | — |
NCT07493330CT.gov Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | — | Not Yet Recruiting | — | — | — |
NCT07414758CT.gov Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy | — | Recruiting | — | — | — |
NCT07209163CT.gov Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07093710CT.gov Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | — | Recruiting | — | — | — |
NCT07081607CT.gov Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. | — | Not Yet Recruiting | — | — | — |
NCT07032532CT.gov Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) | — | Not Yet Recruiting | — | — | — |
NCT06630091CT.gov A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study | — | Recruiting | — | — | — |
NCT06855823CT.gov A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL | — | Recruiting | — | — | — |
NCT06757387CT.gov Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
Show 6 more trialsShow fewer
NCT06739265CT.gov Golidocitinib Plus CHOP in Newly Diagnosed PTCL | — | Recruiting | — | — | — |
NCT07234162CT.gov A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | — | Recruiting | — | — | — |
NCT05963347CT.gov Go-CHOP as the Frontline Therapy for PTCL | — | Recruiting | — | — | — |
NCT06511895CT.gov AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) | — | Completed | — | — | — |
NCT06511869CT.gov AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | — | Completed | — | — | — |
NCT04105010CT.gov Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Golidocitinib (this asset) | Fudan University | P3 | B · 63 |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for Golidocitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | BB · 68 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P2 | B · 60 |
| Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Golidocitinib in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/golidocitinib-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →